This campus houses one of the most advanced facilities of its type in the world, setting new standards not only for biotech process design and automation but also in project execution and delivery. Since its completion, this 90,000-liter-capacity facility has produced significant cancer and arthritis therapies for the U.S. and the world. While all mammalian process-based, the facility has thrived in its ability to campaign manufacture the blockbuster drugs Rituxan (first ever FDA-approved biotech therapy for cancer), Avastin and Actemra.
FPBA created an inspiring, worker-friendly campus with flexibility for unknown growth. The team also master planned an expandable campus (up to 1.2 million square feet) supported by a central utility “spine” to which future buildings could be readily connected. The result of this project is a large-scale, integrated biotech manufacturing campus that was master planned in a design-build collaborative effort with the client, contractors and many engineering disciplines to handle the profound special needs of its client and the biopharmaceutical industry.
